편두통에서의 칼시토닌유전자관련펩티드 표적 치료: 편두통 치료의 새로운 시대

키워드

참고문헌 (75)

1. Benarroch EE, "CGRP : sensory neuropeptide with multiple neurologic implications", Neurology, 77, pp.281~287 (2011)
2. Goadsby PJ, "Vasoactive peptide release in the extracerebral circulation of humans during migraine headache", Ann Neurol, 28, pp.183~187 (1990)
3. Ashina M, "Pearls and pitfalls in human pharmacological models of migraine : 30 years' experience", Cephalalgia, 33, pp.540~553 (2013)
4. Goadsby PJ, "The trigeminovascular system and migraine : studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats", Ann Neurol, 33, pp.48~56 (1993)
5. Cernuda-Morollon E, "Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine", Neurology, 81, pp.1191~1196 (2013)
6. Cernuda-Morollon E, "CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine", Headache, 54, pp.987~995 (2014)
7. Cady R, "An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine", Headache, 54, pp.269~277 (2014)
8. Cernuda-Morollon E, "OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine", Pain, 156, pp.820~824 (2015)
9. Amara SG, "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products", Nature, 298, pp.240~244 (1982)
10. Rosenfeld MG, "Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing", Nature, 304, pp.129~135 (1983)
11. Goadsby PJ, "Joint 1994 wolff award presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311c90", Headache, 34, pp.394~399 (1994)
12. Amrutkar DV, "mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system", Pain, 153, pp.830~838 (2012)
13. Raffaelli B, "The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine", Expert Opin Pharmacother, 18, pp.1409~1415 (2017)
14. Wang X, "Calcitonin gene-related peptide(CGRP)causes endothelium-dependent cyclic AMP, cyclic GMP and vasorelaxant responses in rat abdominal aorta", Neuropeptides, 20, pp.115~124 (1991)
15. Durham PL, "CGRP-receptor antagonists - a fresh approach to migraine therapy?", N Engl J Med, 350, pp.1073~1075 (2004)
16. Durham PL, "Calcitonin gene-related peptide (CGRP) and migraine", Headache, 46(Suppl 1), pp.S3~S8 (2006)
17. Karsan N, "CGRP mechanism antagonists and migraine management", Curr Neurol Neurosci Rep, 15, pp.25~ (2015)
18. Messlinger K, "Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat", Can J Physiol Pharmacol, 73, pp.1020~1024 (1995)
19. Messlinger K, "CGRP and no in the trigeminal system : mechanisms and role in headache generation", Headache, 52, pp.1411~1427 (2012)
20. Ramachandran R, "Neurogenic inflammation and its role in migraine", Semin Immunopathol, 40, pp.301~314 (2018)
21. McCulloch J, "Calcitonin gene-related peptide : functional role in cerebrovascular regulation", Proc Natl Acad Sci U S A, 83, pp.5731~5735 (1986)
22. Durham PL, "Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug", J Neurosci, 19, pp.3423~3429 (1999)
23. Walker CS, "CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?", Br J Pharmacol, 170, pp.1293~1307 (2013)
24. Lassen LH, "CGRP may play a causative role in migraine", Cephalalgia, 22, pp.54~61 (2002)
25. Lipton RB, "CGRP antagonists in the acute treatment of migraine", Lancet Neurol, 3, pp.332~ (2004)
26. Edvinsson L, "CGRP blockers in migraine therapy: where do they act?", Br J Pharmacol, 155, pp.967~969 (2008)
27. Olesen J, "Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine", N Engl J Med, 350, pp.1104~1110 (2004)
28. Ho TW, "Efficacy and tolerability of MK-0974(telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine : a randomised, placebo-controlled, parallel-treatment trial", Lancet, 372, pp.2115~2123 (2008)
29. Connor KM, "Randomized, controlled trial of telcagepant for the acute treatment of migraine", Neurology, 73, pp.970~977 (2009)
30. Chaitman BR, "A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina", Clin Pharmacol Ther, 91, pp.459~466 (2012)
31. Gonzalez-Hernandez A, "Side effects associated with current and prospective antimigraine pharmacotherapies", Expert Opin Drug Metab Toxicol, 14, pp.25~41 (2018)
32. Bell IM, "Calcitonin gene-related peptide receptor antagonists : new therapeutic agents for migraine", J Med Chem, 57, pp.7838~7858 (2014)
33. Ho TW, "Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine", Cephalalgia, 36, pp.148~161 (2016)
34. Dodick DW, "Ubrogepant for the treatment of migraine", N Engl J Med, 381, pp.2230~2241 (2019)
35. Lipton RB, "Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine : the ACHIEVE II randomized clinical trial", JAMA, 322, pp.1887~1898 (2019)
36. Ailani J, "Long-term safety evaluation of ubrogepant for the acute treatment of migraine : phase 3, randomized, 52-week extension trial", Headache, 60, pp.141~152 (2020)
37. Goadsby PJ, "Safety and tolerability of ubrogepant following intermittent, high-frequency dosing : randomized, placebo-controlled trial in healthy adults", Cephalalgia, 39, pp.1753~1761 (2019)
38. Croop R, "Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine : a randomised, phase 3, double-blind, placebo-controlled trial", Lancet, 394, pp.737~745 (2019)
39. Lipton RB, "Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine", N Engl J Med, 381, pp.142~149 (2019)
40. Goadsby PJ, "Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b", 3 study (s17.001), 2019, pp.92, S17.001~
41. Tfelt-Hansen P, "Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine", Headache, 51, pp.118~123 (2011)
42. Edvinsson L, "CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment", Br J Clin Pharmacol, 80, pp.193~199 (2015)
43. Meng J, "Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential", J Cell Sci, 120, pp.2864~2874 (2007)
44. Zhang X, "Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1channels: are we getting closer to solving this puzzle?", Cephalalgia, 36, pp.875~886 (2016)
45. Sun H, "Safety and efficacy of AMG 334 for prevention of episodic migraine : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet Neurol, 15, pp.382~390 (2016)
46. Tepper S, "Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2trial", Lancet Neurol, 16, pp.425~434 (2017)
47. Dodick DW, "ARISE : a phase 3 randomized trial of erenumab for episodic migraine", Cephalalgia, 38, pp.1026~1037 (2018)
48. Goadsby PJ, "A controlled trial of erenumab for episodic migraine", N Engl J Med, 377, pp.2123~2132 (2017)
49. Ashina M, "Sustained efficacy and long-term safety of erenumab in patients with episodic migraine : 4+ year results of a 5-year, open-label treatment period", Cephalalgia, 39, pp.358~427 (2019)
50. Ashina M, "Efficacy and safety of erenumab(AMG334)in chronic migraine patients with prior preventive treatment failure : a subgroup analysis of a randomized, double-blind, placebo-controlled study", Cephalalgia, 38, pp.1611~1621 (2018)
51. Reuter U, "Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful : a randomised, double-blind, placebo-controlled, phase 3b study", Lancet, 392, pp.2280~2287 (2018)
52. Dodick DW, "Effect of fremanezumab compared with placebo for prevention of episodic migraine : a randomized clinical trial", JAMA, 319, pp.1999~2008 (2018)
53. Silberstein SD, "Fremanezumab for the preventive treatment of chronic migraine", N Engl J Med, 377, pp.2113~2122 (2017)
54. Ferrari MD, "Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes(FOCUS) : a randomised, double-blind, placebo-controlled, phase 3b trial", Lancet, 394, pp.1030~1040 (2019)
55. Stauffer VL, "Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial", JAMA Neurol, 75, pp.1080~1088 (2018)
56. Skljarevski V, "Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 phase 3 randomized controlled clinical trial", Cephalalgia, 38, pp.1442~1454 (2018)
57. Detke HC, "Galcanezumab in chronic migraine : the randomized, double-blind, placebo-controlled regain study", Neurology, 91, pp.e2211~e2221 (2018)
58. Ruff DD, "Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure : results from two global randomized clinical trials", Eur J Neurol, 27, pp.609~618 (2020)
59. Mulleners W, "A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine : results from the 3-month double-blind treatment phase of the CONQUER study", J Neurol Sci, 405(Suppl), pp.128~ (2019)
60. Ju MS, "Aglycosylated full-length igg antibodies : steps toward next-generation immunotherapeutics", Curr Opin Biotechnol, 30, pp.128~139 (2014)
61. Ashina M, "Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study(PROMISE-1)", Cephalalgia, 40, pp.241~254 (2020)
62. Lipton RB, "Efficacy and safety of eptinezumab in patients with chronic migraine : PROMISE-2", Neurology, 94, pp.e1365~e1377 (2020)
63. Dodick DW, "CGRP ligand and receptor monoclonal antibodies for migraine prevention : evidence review and clinical implications", Cephalalgia, 39, pp.445~458 (2019)
64. American Headache Society, "The american headache society position statement on integrating new migraine treatments into clinical practice", Headache, 59, pp.1~18 (2019)
65. Aurora SK, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial", Cephalalgia, 30, pp.793~803 (2010)
66. Hepp Z, "Systematic review of migraine prophylaxis adherence and persistence", J Manag Care Pharm, 20, pp.22~33 (2014)
67. Young WB, "The stigma of migraine", PLoS One, 8, pp.e54074~ (2013)
68. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016:a systematic analysis for the global burden of disease study 2016", Lancet, 390, pp.1211~1259 (2017)
69. Sacco S, "European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention", J Headache Pain, 20, pp.6~ (2019)
70. Depre C, "A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina", Headache, 58, pp.715~723 (2018)
71. Yallampalli C, "Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity", Trends Endocrinol Metab, 13, pp.263~269 (2002)
72. Serrano D, "Cost and predictors of lost productive time in chronic migraine and episodic migraine : results from the american migraine prevalence and prevention(AMPP)study", Value Health, 16, pp.31~38 (2013)
73. Lipton RB, "Migraine prevalence, disease burden, and the need for preventive therapy", Neurology, 68, pp.343~349 (2007)
74. Blumenfeld AM, "Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine : results from the second international burden of migraine study(IBMS-II)", Headache, 53, pp.644~655 (2013)
75. Hepp Z, "Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine : a retrospective claims analysis", Cephalalgia, 37, pp.470~485 (2017)

관련 논문AI추천